# US 2014/0271726 A1 · Compositions and methods for predicting hcv susceptibility to antiviral agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271726 A1
- Document ID: US20140271726A1
- Status: Published application
- Kind: A1
- Application number: 13/796,974
- Filed: 2013-03-12
- Published: 2014-09-18
- Earliest claimed: 2013-03-12
- Assignees: Wisconsin Alumni Research Foundation
- Applicants: Wisconsin Alumni Research Foundation
- Inventors: Israr H. Ansari; Robert T. Striker
- Web page: https://patentgrep.com/patent/US20140271726A1

## CPC

- C12Q 1/70: involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)}
- C12Q 1/707: {non-A, non-B Hepatitis, excluding hepatitis D}
- C12N 2770/24211: Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are methods for determining the susceptibility of a hepatitis C virus (HCV) in a patient to anti-viral agents, particularly cyclophilin inhibitors such as cyclosporine A. More particularly, provided herein are methods for determining the amino acid sequence within a region of the HCV NS5A protein and comparing the viral amino acid sequence to that of a reference strain, wherein the existence of at least one variation in the viral genome is indicative that the virus is more or less susceptible to anti-viral agents relative to the reference strain. Also provided are isolated polynucleotide molecules, replicons, and kits that can be used to assay the susceptibility of a particular HCV to an anti-viral agent.

## Claims

### Claim 1

A method for determining susceptibility of a hepatitis C virus (HCV) in a sample to an anti-viral agent, the method comprising determining the amino acid sequence within the HCV NS5A region and comparing said amino acid sequence to that of a reference strain, wherein the existence of at least one variation in the viral amino acid sequence is indicative that the virus is more or less susceptible to the anti-viral agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the at least one variation is in a consensus amino acid sequence corresponding to amino acid residues 305-328 of the wild type HCV NS5A region of SEQ ID NO:3.

### Claim 3 (depends on 2)

The method of claim 2, wherein the at least one variation comprises a proline, isoleucine, arginine, or methionine substitution at the amino acid corresponding to amino acid residue 310 of SEQ ID NO:3.

### Claim 4 (depends on 3)

The method of claim 3, wherein the at least one variation comprises a proline, alanine, isoleucine, methionine or arginine substitution at the amino acid corresponding to amino acid residue 328 of SEQ ID NO:3.

### Claim 5 (depends on 2)

The method of claim 2, wherein the variant consensus sequence is KSRRFX1RALPVWAX2PX3X4X5PPLVEX6, wherein X1 is proline, isoleucine, arginine, or methionine; X3, X4, and X5 can be any amino acid; and X6 is proline, alanine, isoleucine, methionine, or arginine.

### Claim 6 (depends on 5)

The method of claim 5, wherein the variant consensus sequence is KSRRFPRALPVWARPDYNPPLVEP.

### Claim 7 (depends on 1)

The method of claim 1, wherein the anti-viral agent is a cyclophilin inhibitor.

### Claim 8 (depends on 7)

The method of claim 7, wherein the cyclophilin inhibitor is selected from the group consisting of Debio-025, SCY-325, and cyclosporine A (CsA).

### Claim 9 (depends on 8)

The method of claim 8, wherein the cyclophilin inhibitor is CsA.

### Claim 10 (depends on 1)

The method of claim 1, wherein the sample is a clinical sample obtained from a HCV infected patient.

### Claim 11 (depends on 10)

The method of claim 10, wherein the HCV infected patient is a liver-transplant patient.

### Claim 12

An isolated polynucleotide comprising a nucleic acid sequence that encodes for a region within the HCV NS5A protein having at least one variation in a consensus amino acid sequence corresponding to amino acid residues 305-328 of the reference HCV NS5 region of SEQ ID NO:3, wherein the mutated/variant consensus sequence encoded by the polynucleotide is KSRRFX1RALPVWAX2PX3X4X5PPLVEX6, wherein X1 is proline, isoleucine, arginine, or methionine; X3, X4, and X5 can be any amino acid; and X6 is proline, alanine, isoleucine, methionine, or arginine.

### Claim 13 (depends on 12)

The isolated polynucleotide of claim 12, wherein the variant consensus sequence encoded by the polynucleotide is KSRRFPRALPVWARPDYNPPLVEP.

### Claim 14 (depends on 12)

A gene chip comprising at least two isolated polynucleotides according to claim 12.

### Claim 15 (depends on 12)

A kit comprising at least one isolated polynucleotide of claim 12, and a means for determining whether a sample contains a nucleic acid molecule that comprises the nucleotide sequence of the polynucleotide.

### Claim 16 (depends on 15)

The kit of claim 15, wherein the means comprises reagents suitable for a PCR or a hybridization reaction that utilizes the polynucleotide molecule as a primer or a probe.

### Claim 17

A method for treating a HCV infection in an individual, the method comprising determining whether the HCV infection is susceptible to an anti-viral agent, and administering to the individual one or more anti-viral agents selected on the basis of the susceptibility determination, whereby the HCV infection is treated.

### Claim 18 (depends on 17)

The method of claim 17, wherein the individual is a liver transplant patient.

### Claim 19 (depends on 17)

The method of claim 17, wherein the one or more anti-viral agents comprise a cyclophilin inhibitor.

### Claim 20 (depends on 12)

An anti-viral agent-susceptible HCV replicon, comprising the isolated polynucleotide of claim 12.
